Biogen Agrees to $22 Million Settlement of Allegations It Paid Kickbacks Through Foundation
- December 18, 2020
Biogen, Inc. agreed to pay $22 million to resolve claims that it violated the False Claims Act by illegally using foundations as a conduit to cover the copays of Medicare patients taking the pharmaceutical company’s multiple sclerosis drugs, Avonex and Tysabri, the Justice Department announced December 17.
ARTICLE TAGS
You must be logged in to access this content.